Mesoblast shares dived nearly 16 per cent on Tuesday as the powerful US regulator raised more questions around its flagship drug candidate, and its annual loss widened.
The biotech met with the US Food & Drug Administration in the June quarter on potential regulatory approval of remestemcel-L, used to treat acute graft versus host disease (SR-aGVHD) in children, and to treat acute respiratory distress syndrome (ARDS) in adults with COVID-19.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
